Chronic Phase

The patient with chronic-phase CML treated with ima-tinib requires close monitoring to determine response and to adjust therapy accordingly. Complete blood counts should be monitored weekly for at least 1

Recommended follow-up evaluations for patients with CML in chronic phase being treated with imatinib

First year

Every 3 months Every 6 months

Subsequent years Every 3 months Every 6 months Every 12 months

Blood sample CBC and diff FISH analysis QT-PCR Bone marrow Histology Cytogenetics

0 0

Post a comment